Lexicon Pharmaceuticals Inc $1.52

up +0.02


29/8/2014 04:00 PM  |  NASDAQ : LXRX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get LXRX Trend Analysis - it has underperformed the S&P 500 by 63%

Partner Headlines

  1. Benzinga's Top Downgrades

    Benzinga
  2. Gabelli Downgrades Lexicon Pharmaceuticals To Hold

    Benzinga
  3. FOMC To End QE In October; The Container Store Shares Slide

    Benzinga
  4. AeroVironment Surges On Upbeat Results; The Container Store Shares Slide

    Benzinga
  5. Markets Edge Higher; Alcoa Profit Beats Street View

    Benzinga
  6. Morning Market Movers

    Benzinga
  7. US Stock Futures Flat; All Eyes On Fed Minutes

    Benzinga
  8. Lexicon And JDRF Collaborate For Phase 2 Clinical Trial Of LX4211 In Type ...

    Benzinga
  9. 3 Small-Cap Biotechs That Institutions Are Loving

    Benzinga
  10. Mid-Morning Market Update: Markets Open Higher; Citigroup Results Beat ...

    Benzinga
  11. Morning Market Movers

    Benzinga
  12. US Stock Futures Flat; Citigroup Earnings In Focus

    Benzinga
  13. Benzinga's Top Initiations

    Benzinga
  14. UPDATE: Bank of America Initiates Underperform On Lexicon Pharmaceuticals, ...

    Benzinga
  15. Benzinga's Top #PreMarket Losers

    Benzinga
  16. Lexicon Phase 2 Study Of LX1033 In IBS-d Shows Differences Between Placebo ...

    Benzinga
  17. Benzinga's Top Pre-Market Losers

    Benzinga
  18. Lexicon Pilot Study of Telotristat Etiprate In Ulcerative Colitis Achieves ...

    Benzinga
  19. Market Wrap For Tuesday, October 1: Government Down, Markets Up

    Benzinga
  20. Mid-Afternoon Market Update: Markets Remain Up As Government Shutdown Continues

    Benzinga
  21. Mid-Day Market Update: US Stocks Extend Gains; Lexicon Shares Surge

    Benzinga
  22. Mid-Morning Market Update: Markets Rise; Walgreen Earnings Surge 86%

    Benzinga
  23. Morning Market Movers

    Benzinga
  24. Benzinga's Top Pre-Market Gainers

    Benzinga
  25. Lexicon Pharma Reports Results from Trial of LX4211, Says Met Primary Goal, ...

    Benzinga
  26. Lexicon Pharmaceuticals Provides Clinical Pipeline Update

    Benzinga
  27. Stocks Surge as Fiscal Cliff Deal Appears Close

    Benzinga
  28. Mid-Day Market Update: Political Indecision Looms, Yet Markets Rise

    Benzinga
  29. Mid-Morning Market Update: Markets Rise Ahead of Fiscal Cliff, Cott Falls

    Benzinga
  30. Mid-Morning Market Update: Caribou Bought Out; Clearwire Plummets

    Benzinga
  31. Lexicon Pharma Shares Rise Following FDA Fast Track Designation for LX1 ...

    Benzinga
  32. Lexicon Genetics Inc. Reports Operating Results (10-Q)

    GuruFocus
  33. Lexicon Pharma Says Primary Efficacy Endpoint Was Achieved

    Benzinga
  34. Lexicon Prices 17.5M Shares At $2.25 per Share

    Benzinga
  35. Lexicon Announces Proposed Common Stock Offering

    Benzinga
  36. Benzinga's Top Pre-Market Gainers

    Benzinga
  37. Benzinga's Top Pre-Market Gainers

    Benzinga
  38. A Peek Into The Market Before The Trading Starts

    Benzinga
  39. A Peek Into The Market Before The Trading Starts

    Benzinga
  40. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies

    Benzinga
  41. Lexicon Genetics Inc. Reports Operating Results (10-Q)

    GuruFocus
  42. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second ...

    Benzinga
  43. A Peek Into The Market Before The Trading Starts

    Benzinga
  44. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients ...

    Benzinga
  45. SBA Communications Corporation, The Ryland Group Among Stocks Hitting 52-Week ...

    FoxBusiness
  46. Teva Pharmaceutical Industries, Constellation Brands Among Stocks Up on ...

    FoxBusiness
  47. Benzinga's Top Pre-Market Gainers

    Benzinga
  48. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 ...

    Benzinga
  49. LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes

    Benzinga
Trading Center